MerLion to Present Detailed Phase 2 Data on Efficacy of Finafloxacin in Complicated Urinary Tract Infections at International Congress of Chemotherapy and Infection (ICC)

Singapore, 15 September 2015 - MerLion Pharmaceuticals (“MerLion”), a biopharmaceutical company based in Singapore and Berlin, today announced that detailed data from the Phase 2 clinical trial on the efficacy of finafloxacin will be presented at the joint Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC) and International Society of Chemotherapy (ISC) International Congress of Chemotherapy and Infection (ICC), taking place on September 17-21 in San Diego.

Data will be presented during the following sessions:

Rapid Activity of Finafloxacin in Patients with Urinary Tract Infections and Pyelonephritis Evaluated in Phase 2 Clinical Studies
Date and time: Sunday, September 20, 2015 11:00 AM - 1:00 PM
Session info: 171. Genitourinary and Sexually Transmitted Infections (Poster Session)
Abstract number: L-1250

Rapid Activity of Finafloxacin in Patients with Urinary Tract Infections and Pyelonephritis Evaluated in Phase 2 Clinical Studies
Date and time: Sunday, September 20, 2015 11:00 AM - 1:00 PM
Session info: 171. Genitourinary and Sexually Transmitted Infections (Poster Session)
Abstract number: L-1251

Pharmacodynamics (PD) of Finafloxacin, Ciprofloxacin and Levofloxacin in Serum and Urine against Extended-Spectrum Beta-Lactamase (ESBL) Producing Enterobacteriaceae Isolated from Urinary Tract
Infections (UTIs)
Date and time: Saturday, September 19, 2015 11:00 AM - 1:00 PM
Session info: 080. Pharmacokinetics/Pharmacodynamics (PK/PD) of Agents against Gram-Negative Bacteria (Poster Session)
Abstract number: A-477

Efficacy of Finafloxacin Against Francisella tularensis Strain SchuS4
Date and time: Friday, September 18, 2015 12:00 - 2:00 PM
Session info: 008. New Drugs against Resistant Infections (Poster Session)
Abstract number: B-077

Contacts:

MerLion:                                                             Instinctif Partners (for media enquiries):

David Dally, CEO                                              Sue Charles / Gemma Howe
Tel: +65 6778 5700                                          Tel: +20 7866 7860
E-mail: enquiry@merlionpharma.com         E-mail: merlion@instinctif.com

About MerLion Pharmaceuticals

MerLion Pharmaceuticals Pte Ltd is a biopharmaceutical company focused on developing its antibacterial candidate, finafloxacin. MerLion is a privately held company supported by a group of leading global investors including Aravis Venture Partners, Bio*One Capital (a subsidiary of EDBI), Heidelberg Capital and Nomura Research & Advisory. MerLion Pharmaceuticals Pte Ltd is headquartered in Singapore with clinical development operations in Berlin, Germany. For more information please visit www.merlionpharma.com.

About Finafloxacin

Finafloxacin is a fluoroquinolone antibiotic that demonstrates a substantially improved therapeutic profile over the existing gold standard and greater utility in treating many severe infections, including those caused by a number of resistant Gram-negative pathogens. This superior profile is a result of finafloxacin’s unique chemical structure: in the hostile acidic conditions found at the sites of nearly all infections there is a substantially higher take-up and accumulation of finafloxacin in bacterial cells, as well as superior binding of the molecule to the two fluoroquinolone targets. Most other antibiotics, including other fluoroquinolones, have decreased activity in these acidic conditions where their effectiveness is most needed.

MerLion has developed IV and oral formulations of finafloxacin with equivalent bioavailability, offering physicians the choice of initially treating infections in hospital or at out-patient infusion centres for one to three days with the IV regimen, then allowing patients to complete their treatment at home; reducing the risk of complications and/or secondary infections.